Frequently Asked Questions about Lexaria Bioscience Corp. (LEXX)

Name: Lexaria Bioscience Corp. (LEXX) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Lexaria Bioscience Corp. (LEXX) do?

Accepted Answer

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-abso...

Question 2

Is Lexaria Bioscience Corp. (LEXX) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of LEXX reveals an Altman Z-Score of undefined and a Piotroski F-Score of undefined/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if LEXX fits their risk profile.

Question 3

What is the current P/E ratio for LEXX?

Accepted Answer

As of the latest trading session, Lexaria Bioscience Corp. (LEXX) has a trailing P/E ratio of -2.10.

Question 4

Who is the CEO of Lexaria Bioscience Corp.?

Accepted Answer

The current Chief Executive Officer of Lexaria Bioscience Corp. is Richard C. Christopher.

Question 5

What was LEXX's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Lexaria Bioscience Corp. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does LEXX pay a dividend?

Accepted Answer

Lexaria Bioscience Corp. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does LEXX have?

Accepted Answer

In its latest reporting period, Lexaria Bioscience Corp. generated $-0.01B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of Lexaria Bioscience Corp.?

Accepted Answer

The Price-to-Book (P/B) ratio for Lexaria Bioscience Corp. (LEXX) is currently 4.61.

Question 9

What is the Price-to-Sales (P/S) ratio of LEXX?

Accepted Answer

Based on trailing twelve-month data, Lexaria Bioscience Corp. (LEXX) trades at a Price-to-Sales (P/S) ratio of 39.26.

Question 10

What is Lexaria Bioscience Corp.'s Return on Equity (ROE)?

Accepted Answer

Lexaria Bioscience Corp. (LEXX) has a Return on Equity (ROE) of N/A, representing its profitability relative to shareholder equity.

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-08	4.2M	1.6M	2.6M	109.3K	-1.7M
2024-08	8.9M	1.2M	7.7M	137.4K	-6.4M
2023-08	3.1M	403.9K	2.7M	164K	-1.2M
2022-08	7.8M	201.4K	7.6M	50K	-5.8M
2021-08	13.3M	203.3K	13.1M	97.3K	-10.8M

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-08	4.2M	1.6M	2.6M	109.3K	-1.7M
2024-08	8.9M	1.2M	7.7M	137.4K	-6.4M
2023-08	3.1M	403.9K	2.7M	164K	-1.2M
2022-08	7.8M	201.4K	7.6M	50K	-5.8M
2021-08	13.3M	203.3K	13.1M	97.3K	-10.8M